Arnold Lippa

About Arnold Lippa
Dr. Lippa has extensive expertise in drug discovery and development, governmental regulations, corporate and research management, as well as merchant and investment banking. He presently is Executive Chairman of the Board, Chief Scientific Officer and Interim Chief Executive Officer at RespireRx Pharmaceuticals Inc., a clinic stage company which is pursuing innovative and revolutionary treatments to combat diseases caused by disruption of normal neuronal signaling. Dr. Lippa also is a Senior Managing Director and founder of T Morgen Capital LLC, his family office and a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a boutique investment bank and securities firm. Dr. Lippa co-manages, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Since 2015, Dr. Lippa has also been a member of the Board of Directors of Hepion Pharmaceuticals, Inc. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005. He also has founded and managed a number of companies conducting research in the areas of AIDS, otolaryngology, hypertension and metabolic disorders. Dr. Lippa began his career at the Medical Research Division of American Cyanamid where, as Director of Molecular Neurobiology, he was an early pioneer in identifying the role of cholinergic dysfunction in the etiology of dementia, which led to the use of acetylcholinesterase inhibitors for the treatment of Alzheimer’s dementia. He also identified GABA receptor heterogeneity, based on his discovery of the first drugs to act as positive allosteric modulators at specific GABA receptor sub-types. In a series of translational studies conducted at DOV, this class of drugs was shown to act selectively at the alpha1 GABA-A receptor subtype and to display anti-anxiety properties in animal models and in human patients without producing the sedation and motor impairment produced by non-selective benzodiazepines, such as Valium and Xanax. While at DOV, he also discovered and developed a series of drugs that blocked the reuptake of norepinephrine, serotonin and dopamine (“triple reuptake inhibitors”), one of which is in late stage clinical development. Most recently, at RespireRx, Dr. Lippa has focused his research on: (1) ampakines, positive allosteric modulators of the AMPA glutamate receptor, and their potential use for the treatment of Attention Deficit Hyperactivity Disorder, recovery from spinal cord injury, opioid-induced respiratory depression and certain forms of cognitive decline; as well as (2) the use of cannabinoids for the treatment of breathing disorders, particularly sleep apneas.

Participation in events